



国内版 国际版

GLP-1RA and SGLT-2i combination - are we exploiting their full pot



Chat with Bing

Sign in



ALL IMAGES VIDEOS

29,100 Results Any time

Efficacy and safety of GLP-1 receptor agonists as add-on ...

<https://www.nature.com/articles/s41598-019-55524-w>

Dec 18, 2019 · Considering their specific mechanistic synergy, tackling multiple pathophysiological defects of type 2 diabetes, the combination of GLP-1RA and SGLT-2i ...

Cited by: 7 Author: Marco Castellana, Angelo Cignarelli, Fran...
Publish Year: 2019

Search Tools

Turn off Hover Translation (关闭取词)

Efficacy and safety of GLP-1 receptor agonists as add-on ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920368>

Considering their specific mechanistic synergy, tackling multiple pathophysiological defects of type 2 diabetes, the combination of GLP-1RA and SGLT-2i is expected to result in further decrease in HbA 1c with no further risk of hypoglycaemia, greater weight loss, and enhanced potential for cardiovascular and renal benefits, as compared with ...

Cited by: 7 Author: Marco Castellana, Angelo Cignarelli, Fran...
Publish Year: 2019

ALL

IMAGES

VIDEOS

61,100 Results

Any time ▾

Effects of Glucagon-Like Peptide-1 Receptor Agonists ...

<https://www.ahajournals.org/doi/full/10.1161/JAHA.119.015716>

Patients under **GLP-1RA**, **SGLT-2i**, and **their combination** achieved a greater reduction of PWV, central SBP, and brachial SBP than those under insulin ($P < 0.05$, for comparisons; Table 3, Figure 1B and 1C), despite a similar reduction of HbA1c ($F = 2.073$, P for interaction for treatment = 0.237) at 12

Cited by: 4

Author: Ignatios Ikonomidis, George Pavlidis, John ...

Publish Year: 2020

Glycemic efficacy and safety of glucagon-like peptide-1 ...

<https://www.sciencedirect.com/science/article/pii/S0168822719311209>

Dec 01, 2019 · Besides glycemic parameters, **we** have demonstrated that the **GLP-1RA/SGLT-2i combination** resulted in a significant body weight loss by 1.95 kg and a decrease in systolic blood pressure levels by 3.64 mm Hg, compared to **SGLT-2i** alone; however, it did not affect any of lipid profile parameters and diastolic blood pressure.

Cited by: 3

Author: Dimitrios Patoulas, Konstantinos Stavropo...

Publish Year: 2019

Combination Therapy With GLP-1 Receptor Agonist and SGLT2 ...

<https://www.researchgate.net/publication/316358518...>

GLP-1RA or **GLP-1RA+SGLT-2i** provided a greater increase of **global work index** (12.7% and 17.4%) compared with insulin or **SGLT-2i** (3.1% and 2%).

Do GLP-1RA and SGLT-2i reduce cardiovascular events in ...

<https://www.researchgate.net/publication/333644011...>

Pooled results showed no significant difference in the incidence of MACE between diabetic medications

Name of Journal: *World Journal of Diabetes*

Manuscript NO: 58684

Manuscript Type: ORIGINAL ARTICLE

Observational Study

GLP-1RA and SGLT-2i combination - are we exploiting their full potential in a real life setting

GLP-1RA and SGLT-2i combination - in a real life setting

Abstract

BACKGROUND

The sodium/glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like-1 receptor agonists (GLP-1 RA) are antidiabetic agents effective both in HbA1c reduction (with a low risk of hypoglycemia) and cardiovascular event prevention. In patients with type 2 diabetes, the add-on value of combination therapy of GLP-1RA and an SGLT-2i seems promising.

Match Overview

1	Internet 98 words crawled on 28-Jan-2020 link.springer.com	2%
2	Internet 24 words crawled on 25-Jun-2020 www.unirepostory.svkri.uniri.hr	<1%
3	Crossref 17 words Juana Carretero Gómez, José Carlos Arévalo Llorido, Ricardo Gómez Hueigas, Dolores García de Lucas et al. "Combinatio	<1%
4	Crossref 14 words Marco Castellana, Angelo Cignarelli, Francesco Brescia, Luigi Laviola, Francesco Giorgino. "GLP-1 Receptor Agonist Added	<1%
5	Crossref 14 words A Ramírez de Arellano Serna, P Mezquita-Raya, G Vega-Hernandez, R Wojcik, M Schlueter. "Liraglutide Versus Dapagliflo	<1%

国内版 国际版

Glucagon-like-1 receptor agonists and sodium/glucose cotranspo



ALL IMAGES VIDEOS

71,500 Results

Any time ▾

Glucagon-like peptide-1 receptor agonists or sodium ...

<https://www.sciencedirect.com/science/article/pii/S1262363620300562>

Sep 01, 2020 · Objective. As **sodium-glucose cotransporter-2 inhibitors** (SGLT-2is) and glucagon-like peptide-1 **receptor agonists** (GLP-1RAs) are second-line treatment options in type 2 diabetes mellitus (T2DM), our study sought to provide precise effect estimates regarding the role of GLP-1RAs vs SGLT-2is as add-on treatments in patients uncontrolled by metformin monotherapy.

Author: D. Patoulas, A. Katsimardou, M.-S. ... **Publish Year:** 2020

[PDF] Combining Glucagon-Like Peptide 1 Receptor Agonists and ...

<https://spectrum.diabetesjournals.org/content/diaspect/early/2020/04/02/ds19-0031.full.pdf>

Apr 02, 2020 · Combining Glucagon-Like Peptide 1 **Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors** to Target Multiple Organ Defects in Type 2 Diabetes John E. Anderson The Frist Clinic, Nashville, TN Long-term risks of macro-andmicrovascular complications may be reduced in people with type 2 diabetes who achieve early and sustained glycemic control.

Author: John E. Anderson **Publish Year:** 2020

Combining Glucagon-Like Peptide 1 Receptor Agonists and ...

<https://spectrum.diabetesjournals.org/content/33/2/165> ▾

May 01, 2020 · Long-term risks of macro- and microvascular complications may be reduced in people with type 2 diabetes who achieve early and sustained glycemic control. Delays in attaining A1C goals are associated with poor long-term cardiovascular (CV) outcomes. Glucagon-like peptide 1 (GLP-1) **receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors** are **glucose ...**

Author: John E. Anderson **Publish Year:** 2020

Comparison of the Effects of Glucagon-Like Peptide ...

<https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.118.038868>